U.S. Markets open in 2 hrs 56 mins

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,461.50+9.50 (+0.65%)
As of 11:18AM BST. Market open.
Full screen
Previous Close1,452.00
Open1,450.00
Bid1,461.00 x 175400
Ask1,462.00 x 417900
Day's Range1,444.50 - 1,463.50
52 Week Range1,444.00 - 1,745.56
Volume2,165,651
Avg. Volume6,913,058
Market Cap70.96B
Beta1.15
PE Ratio (TTM)37.38
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.01 (5.14%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Reuters3 hours ago

    GSK's new triple lung drug beats other modern inhalers in study

    GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments. Britain's biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair. Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca's long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

  • FDA OKs Glaxo's inhaler, first one to combine 3 medicines
    Associated Press14 hours ago

    FDA OKs Glaxo's inhaler, first one to combine 3 medicines

    TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.

  • Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
    Zacks15 hours ago

    Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD

    The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.